Skip to content
10-Q

Quarterly Report

SPYRE THERAPEUTICS, INC. SYRE

0001636282-25-000089

← back to feed
Filed
Aug 5, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2025 · Jul 31, 2025 60.4M sh
Operating Cash Flow Q2 2025 · Jun 30, 2025 −$87.56M
Cash And Equivalents Q2 2025 · Jun 30, 2025 $81.66M
Cash And Equivalents Q2 2025 · Dec 31, 2024 $89.42M
Stockholders Equity Q2 2025 · Jun 30, 2025 $455.77M
Stockholders Equity Q2 2025 · Mar 31, 2025 $482.61M
Stockholders Equity Q2 2025 · Dec 31, 2024 $517.8M
Current Liabilities Q2 2025 · Jun 30, 2025 $83.06M
Current Liabilities Q2 2025 · Dec 31, 2024 $54.06M
Total Liabilities Q2 2025 · Jun 30, 2025 $83.06M
Total Liabilities Q2 2025 · Dec 31, 2024 $90.68M
Current Assets Q2 2025 · Jun 30, 2025 $538.83M
Current Assets Q2 2025 · Dec 31, 2024 $608.47M
Total Assets Q2 2025 · Jun 30, 2025 $538.83M
Total Assets Q2 2025 · Dec 31, 2024 $608.48M
Eps Diluted Q2 2025 · Jun 30, 2025 −$1.09
Sga Expense Q2 2025 · Jun 30, 2025 $11.79M
Sga Expense Q2 2025 · Jun 30, 2025 $23.73M
Net Income Q2 2025 · Jun 30, 2025 −$36.72M
Net Income Q2 2025 · Jun 30, 2025 −$81.49M
Net Income Q2 2025 · Mar 31, 2025 −$44.77M
Operating Income Q2 2025 · Jun 30, 2025 −$41.94M
Operating Income Q2 2025 · Jun 30, 2025 −$95.5M